Skip to main content

Table 1 Baseline characteristics of the patients included in the DECA criteria for AC severity and control validation study (N = 128)

From: Validation of the DECA criteria for allergic conjunctivitis severity and control

Age, years, mean (SD) 34.4 (12.1)
Gender, female, N (%) 93 (72.7)
Allergic comorbidities, N (%)
 AR 128 (100.0)
 Asthma 53 (41.4)
 Atopic dermatitis 14 (10.9)
 Urticaria 11 (8.6)
 Contact dermatitis 4 (3.1)
 Food allergy 4 (3.1)
 Other 14 (10.9)
Type of AC sensitization, N (%)
 Perennial 40 (32.5)
 Seasonal 31 (25.2)
 Both 52 (42.3)
rTOSS score, mean (SD) 5.4 (2.3)
Hyperemia (Efron scale), N (%)
 Normal 26 (20.3)
 Trace 62 (48.4)
 Mild 29 (22.7)
 Moderate 11 (8.6)
AC duration, N (%)
 Intermittent 44 (34.4)
 Persistent 84 (65.6)
Items reported (DECA), N (%)
 Bothersome symptoms 116 (90.6)
 Affecting vision 39 (30.5)
 Interference with academic or work tasks 54 (42.2)
 Interference with daily activity, reading, sport 66 (51.6)
Severity (DECA criteria), N (%)
 Mild (no items affected) 10 (7.8)
 Moderate (1–3 items affected) 93 (72.7)
 Severe (4 items affected) 25 (19.5)
Control (DECA criteria), N (%)
 Controlled 27 (21.1)
 Not controlled 101 (78.9)
Ophthalmic treatments at baseline, N (%)
 Azelastine 34 (26.6)
 Ketotifen 11 (8.6)
 Olopatadine 3 (2.3)
 Levocabastine 1 (0.8)
 Others 1 (0.8)
Nasal treatments at baseline, N (%)
 Budesonide 2 (1.6)
 Fluticasone 12 (9.4)
 Mometasone 22 (17.2)
 Triamcinolone 1 (0.8)
 Fluticasone furoate 43 (33.6)
 Fluticasone/azelastine combination 41 (32.0)
  1. AC: allergic conjunctivitis; AR: allergic rhinitis; DECA: Spanish document on allergic conjunctivitis; rTOSS: reflective total ocular symptom score; SD: standard deviation